ALETA-001 Was Developed to Address the Urgent Unmet Need of Patient Relapse After CD19-Targeted CAR T-Cell Cancer Treatment. Click the link above to read all about it.
Aleta’s -001 preclinical development paper has been published. This takes Aleta from MOA and efficacy through dose estimation, PK and early protein CMC. Click the link above to read all about it.
Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today released new preclinical results at the 25th American Society of Gene & Cell Therapy Annual Meeting, held in Washington DC and in a virtual platform on May 16-19, 2022. ASGCT is the premier showcase for advances in cell and gene engineering, development and clinical translation.
The presentation featured preclinical data that advance Aleta’s programs in development for the treatment of multiple myeloma and acute myeloid leukemia. These programs leverage the company’s proprietary CAR T Engager technology – multi-antigen targeting systems designed to expand the functionality of conventional cell therapeutics.